American Association for Respiratory Care: Industry Watch
February 26, 2021
February 26, 2021
IRVING, Texas, Feb. 26 -- The American Association for Respiratory Care issued the following news:
New COVID-19 Therapies Join ACTIV-2 Trial
Promising new therapies have been added to the COVID-19 outpatient treatment study, ACTIV-2. The additional agents include:
* A combination of two monoclonal antibodies (AZD8895 and AZD1061) from AstraZeneca studied as an infusion administered over 15 minutes and an intramuscular injection;
* A nebulize . . .
New COVID-19 Therapies Join ACTIV-2 Trial
Promising new therapies have been added to the COVID-19 outpatient treatment study, ACTIV-2. The additional agents include:
* A combination of two monoclonal antibodies (AZD8895 and AZD1061) from AstraZeneca studied as an infusion administered over 15 minutes and an intramuscular injection;
* A nebulize . . .